Parkinson Disease Psychosis
13
3
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.7%
1 terminated out of 13 trials
80.0%
-6.5% vs benchmark
15%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Effect of Food and Age on the Pharmacokinetics of LY03017
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
Bioequivalence Study of Pimavanserin 34 mg Capsule
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
Hallucinations in Parkinson's Disease
Presence Hallucination in Parkinson's Disease
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis